A study of two drugs for untreated advanced liver cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two medications, SHR-2524 and bevacizumab, as a first treatment for people with advanced hepatocellular carcinoma (a type of liver cancer) that has not been treated with cancer drugs before. The goal is to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced liver cancer (hepatocellular carcinoma) confirmed by biopsy or imaging.
- Your liver cancer must be at a stage called B or C on the Barcelona scale, which means it is more advanced.
- You cannot have received any previous cancer drug treatment for liver cancer.
- You must have at least one tumor that can be measured on a scan.
- Your liver function must be fairly good, as measured by the Child-Pugh score (A or B7).
- Your daily activities should be mostly unaffected (ECOG score 0 or 1).
- You must not have had certain types of liver cancer like fibrolamellar or mixed cell types.
- You cannot have another active cancer in the last 5 years, except for some cured skin or early stage cancers.
- You cannot have had an organ transplant, like a liver transplant.
- You must not have had serious bleeding or stomach/intestinal problems in the last few months.
- You must not have HIV or other immune system problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SH006 combined with another treatment against a standard drug (regorafenib) for advanced liver cancer. It is for people whose cancer has stopped responding to immunotherapy, and the goal is to see if it helps them live longer or shrinks the tumor.
This study tests whether combining a standard treatment for liver cancer (TACE) with three additional medications can help people whose cancer cannot be cured. The goal is to see if the combination is more effective than TACE alone.
This trial tests a new combination of three drugs (SHR-8068, adebrelimab, and bevacizumab) against two standard immunotherapy combinations (sintilimab or atezolizumab plus bevacizumab) for people with advanced liver cancer who haven't had systemic treatment before. The goal is to see if the new combo works better for shrinking or controlling the cancer.
This trial tests a new drug combination (ZG005 plus bevacizumab) against a standard one (sintilimab plus bevacizumab) as the first treatment for advanced liver cancer that cannot be removed by surgery. The goal is to see if the new combination works better at shrinking tumors or delaying progression.
This trial tests a new combination of drugs for people with advanced liver cancer who have not had prior treatment. It compares the study drug QL1706 plus standard treatments to see if it can help shrink tumors or slow the disease.
This trial tests a combination of an immunotherapy drug (adebrelimab) and a targeted therapy (bevacizumab) given through a vein or directly into the liver artery, along with standard chemotherapy directly into the liver artery, for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this approach can shrink or control the cancer.
Hear when a new Advanced Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.